Total Synthesis of Neuroprotective Dictyoquinazol A, B, and C

  title={Total Synthesis of Neuroprotective Dictyoquinazol A, B, and C},
  author={Chang Ho Oh and Chung Hyun Song},
  journal={Synthetic Communications},
  pages={3311 - 3317}
  • C. Oh, C. Song
  • Published 1 September 2007
  • Chemistry
  • Synthetic Communications
Abstract A new protective compound, dictyoquinazol A, was synthesized starting from 5‐methoxy‐2‐nitrobenzoic acid in six‐steps in 36% overall yield. Two derivatives B and C, isolated from the mushroom Dictyophora indusiata, were also synthesized from Dictyoquinazole A. 
Structures and Biological Activities of Alkaloids Produced by Mushrooms, a Fungal Subgroup
This review covers the findings of the last 20 years related to the isolation, structures, and biological activities of the alkaloids produced by mushrooms, a fungal subgroup, and their potential to develop drugs and agrochemicals.
Synthesis of N-Heteropolycyclic Compounds Including Quinazolinone Skeleton Using Friedel–Crafts Alkylation
Abstract A simple method to synthesize N-heteropolycyclic quinazolinones was developed including Knoevenagel condensation of quinazolines and aldehydes and Friedel–Craft alkylation as key steps.
The Chemistry, Pharmacology and Therapeutic Potential of the Edible Mushroom Dictyophora indusiata (Vent ex. Pers.) Fischer (Synn. Phallus indusiatus)
Of the bioactive compounds, the chemistry of the polysaccharides as major bioactive components primarily the β-glucan with side branches of β-(1→6)-glucosyl units are discussed, while small molecular weight compounds include terpenoids and alkaloids.
Edible and Medicinal Mushrooms: Emerging Brain Food for the Mitigation of Neurodegenerative Diseases.
In this review, the scientific information on edible and culinary mushrooms with regard to their antidementia/AD active compounds and/or pharmacological test results are summarized and may be regarded as functional foods for the mitigation of neurodegenerative diseases.
Syntheses of indolo[1,2-a]quinazolinone derivatives via palladium catalyzed intramolecular C–H amidation
The synthesis of indolo[1,2-a]quinazolinone starting from 2-iodobenzamide and indole derivatives is reported, followed by an intramolecular C–H amidation using a palladium catalyst.
Synthesis of 3-substituted and 2,3-disubstituted quinazolinones via Cu-catalyzed aryl amidation.
CuI/4-hydroxy-L-proline catalyzed coupling of N-substituted o-bromobenzamides with formamide takes place at 80 °C, affording 3-substituted quinazolinones directly. Under these conditions other amides


Dictyoquinazols A, B, and C, new neuroprotective compounds from the mushroom Dictyophora indusiata.
Dictyoquinazols protected primary cultured mouse cortical neurons from glutamate- and NMDA-induced excitotoxicities in a dose-dependent manner.
Neuroprotective bibenzyl glycosides of Stemona tuberosa roots.
Three new bibenzyl glycosides characterized as stilbostemin B, H, and I significantly protected human neuroblastoma SH-SY5Y cells from 6-hydroxydopamine-induced neurotoxicity.
Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists: structure-activity relationship of the C-2 side chain tether.
New AMPA receptor antagonists, containing the methylamino tether group, have been identified from this effort, and the relative potencies of the new compounds ranged from 11 nM to greater than 10 microM.
The role of excitatory amino acids and NMDA receptors in traumatic brain injury.
Brain injury induced by fluid percussion in rats caused a marked elevation in extracellular glutamate and aspartate adjacent to the trauma site, which contributes to delayed tissue damage after brain trauma.
The role of glutamate in neurotransmission and in neurologic disease.
Pharmacologic manipulation of the glutamatergic system may have great potential for the rational treatment of a variety of neurologic diseases.
AMPA receptor agonists, antagonists and modulators: their potential for clinical utility
From the understanding of neuronal circuitry and its involvement in brain function, agonists and positive allosteric modulators are predicted to improve the negative symptomatology in schizophrenia, and to improve memory, behavioural and cognition skills in dementias associated with neurodegenerative disorders or trauma.